Detailed Information on Publication Record
2016
Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas
ZAMBO, Iva, Markéta HERMANOVÁ, Danica ZAPLETALOVÁ, Jan ŠKODA, Peter MÚDRY et. al.Basic information
Original name
Expression of nestin, CD133 and ABCG2 in relation to the clinical outcome in pediatric sarcomas
Authors
ZAMBO, Iva (203 Czech Republic, belonging to the institution), Markéta HERMANOVÁ (203 Czech Republic, belonging to the institution), Danica ZAPLETALOVÁ (703 Slovakia, belonging to the institution), Jan ŠKODA (203 Czech Republic, belonging to the institution), Peter MÚDRY (203 Czech Republic, belonging to the institution), Michal KÝR (203 Czech Republic, belonging to the institution), Karel ZITTERBART (203 Czech Republic, belonging to the institution), Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution) and Renata VESELSKÁ (203 Czech Republic, guarantor, belonging to the institution)
Edition
Cancer Biomarkers, Amsterdam, IOS Press, 2016, 1574-0153
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30209 Paediatrics
Country of publisher
Netherlands
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 2.274
RIV identification code
RIV/00216224:14310/16:00088884
Organization unit
Faculty of Science
UT WoS
000381114300014
Keywords in English
rhabdomyosarcoma;Ewing sarcoma;osteosarcoma;cancer stem cell markers;prognosis
Tags
International impact, Reviewed
Změněno: 5/4/2017 18:45, Ing. Andrea Mikešková
Abstract
V originále
Nestin, CD133 and ABCG2 are recently discussed as putative markers, co-expression of which might determine a cancer stem cell (CSC) phenotype in sarcomas. Our study is focused on immunohistochemical analysis of nestin, CD133 and ABCG2 expression in rhabdomyosarcoma, Ewing sarcoma and osteosarcoma. Furthermore, we also analyzed the possible correlation of nestin, CD133 and ABCG2 expression levels with the patient outcome to identify potential prognostic values of these three putative CSC markers in the same cohorts. Using immunohistochemistry, expression of nestin, CD133 and ABCG2 was analyzed in 24 rhabdomyosarcoma, 22 Ewing sarcoma and 10 osteosarcoma tissue samples and expression levels of these markers were correlated with clinical outcome. High nestin levels indicate poor prognosis in patients with Ewing sarcoma (P = 0.001), and high CD133 expression is associated with shorter survival in rhabdomyosarcoma patients (P = 0.002). In contrast, no significant relationship was found between ABCG2 expression and the clinical outcome. Our analysis represents the first complex study of these three putative CSCs markers together in three different types of pediatric sarcomas and showed their possible prognostic values in these tumors.
Links
| NT13443, research and development project |
|